Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients : data from the INC-EU Prospective Observational European Neutropenia Study.

Schwenkglenks, Matthias;Pettengell, Ruth;Jackisch, Christian;Paridaens, Robert;Leonard, Robert;et.al.
(2011) Supportive Care in Cancer — Vol. 19, n° 4, p. 483-490 (2011)

Files

Svrshare1cvmedecinsDIALHématoSupportCareCancer2011SchwenkglenksM.pdf
  • Closed Access
  • Adobe PDF
  • 165.42 KB
Request a copy
SchwenkglenksMetalSupportCareCancer2011.pdf
  • Restricted Access
  • Adobe PDF
  • 165.42 KB
Request a copy

Details

Authors
  • Schwenkglenks, Matthias
    Author
  • Pettengell, Ruth
    Author
  • Jackisch, Christian
    Author
  • Paridaens, Robert
    Author
  • Bosly, AndréUCLouvain
    Author
  • Leonard, Robert
    Author
Show more
Abstract
Chemotherapy-induced neutropenia (CIN) places patients at risk of life-threatening infections. While reduction of chemotherapy dose or delay of the subsequent treatment cycle and, consequently, reduction of relative dose intensity (RDI) may limit myelotoxicity, these actions can also impact adversely on treatment outcome and should be avoided in adjuvant settings.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Schwenkglenks, M., Pettengell, R., Jackisch, C., Paridaens, R., Constenla, M., Bosly, A., Szucs, T. D., & Leonard, R. (2011). Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients : data from the INC-EU Prospective Observational European Neutropenia Study. Supportive Care in Cancer, 19(4), 483-490. https://doi.org/10.1007/s00520-010-0840-y (Original work published 2011)